Why Immunome, Inc.’s (IMNM) Stock Is Down 5.21%
As of Friday, July 10, Immunome, Inc.’s IMNM share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Commentary & Analysis
Why Immunome, Inc.’s (IMNM) Stock Is Down 6.47%
As of Tuesday, June 02, Immunome, Inc.’s IMNM share price has dipped by 6.47%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Immunome, Inc.’s (IMNM) Stock Is Up 5.35%
As of Monday, May 11, Immunome, Inc.’s IMNM share price has surged by 5.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immunome, Inc.’s (IMNM) Stock Is Up 5.67%
As of Friday, April 17, Immunome, Inc.’s IMNM share price has surged by 5.67%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immunome, Inc.’s (IMNM) Stock Is Up 5.31%
As of Monday, April 13, Immunome, Inc.’s IMNM share price has surged by 5.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,577.6 | $252.6 | 57% |
|
| Shares Out (Mil) | 113.1 | 52.3 | 65% |
|
| Institutional Ownership | 98.9% | 92.1% | 83% |
|
| Float (Mil) | 108.3 | 40.2 | 63% |
|
| Beta | 2.12 | 0.95 | 93% |
|
| Avg Daily Volume (000s) | 776 | 455 | 66% |
|
| Price Change (52-week) |
111.7% | 52.9% | 93% |
|
| Growth | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (64.2%) | (9.9%) | 5% |
|
| EPS (5yr) | 14.3% | 16.0% | 54 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (11.9%) | (15.6%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 11 | |
| Current EPS | ($0.505) | ($2.125) | ($2.120) | |
| Month Ago EPS | ($0.505) | ($2.125) | ($2.097) | |
| # Rev Up | 3 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.582) | ($2.371) | ($2.114) | |
| Year/Year Chg | 6.1% | (12.6%) | (64.4%) | |
| Financials | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $38 | 5% |
|
| Net Income (TTM) (Mil) | ($225) | ($43) | 6% |
|
| EPS (TTM) | ($2.345) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($197) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $325 | $5 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $5 | 23% |
|
| Enterprise Value (Q1) (Mil) | $1,935 | $180 | 49% |
|
| Valuation | IMNM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.38 | 2.56 | 75% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (46.7%) | (49.8%) | 12% |
|
| ROE | (50.1%) | (55.5%) | 15% |
|
| Liabilities to Assets | 5.0% | 30.3% | 2% |
|
| F-Score | 4 | 3 | 34% |
|
Immunome, Inc. did not pass any screens on 7/31/2026.
